Pharmacology of Indomethacin: Indomethacin is a non-selective COX inhibitor that blocks prostaglandin synthesis.
$\text{PGE}_2$ and $\text{PGI}_2$ (prostacyclin) maintain patency of the ductus arteriosus (DA) in fetal life through vasodilation. When these prostaglandins are inhibited by indomethacin after 36 weeks, the DA undergoes premature constriction -- i.e., $\textbf{premature closure of PDA}$.
Clinical uses of this mechanism:
- Indomethacin is used therapeutically to close a symptomatic PDA in $\textbf{preterm neonates}$.
- As a tocolytic (stops preterm labour) it is used before 32 weeks; after 36 weeks it risks premature DA closure.
Why not teratogenic? Teratogenicity implies structural birth defects caused during organogenesis (first trimester). Indomethacin's fetal effects are pharmacodynamic (prostaglandin inhibition), not teratogenic.
\[\boxed{\text{Premature closure of PDA}}\]